Alintegimod (7HP349)
aPD-1-resistant solid tumors
Phase 1b/2aActive
Key Facts
About 7 Hills Pharma
7 Hills Pharma is a privately held, clinical-stage biotech advancing a novel platform of integrin-targeted small molecule agonists. Its lead asset, Alintegimod, is in a Phase 1b/2a trial to overcome anti-PD-1 resistance in solid tumors, while a second program, 7HP935, is in IND-enabling studies to improve stem cell therapies. The company has demonstrated strong non-dilutive funding prowess, securing over $34 million in grants from entities like the NIH and CPRIT to advance its pipeline. With a focused team and a promising mechanism of action to modulate the tumor microenvironment, 7 Hills is positioning itself as a potential key player in next-generation immunotherapy combinations.
View full company profile